Fig. 9.

Intratumor MLKL-mRNA treatment reduces tumor growth in humanized mice. a Human melanoma cell lines (501 Mel, BLM, SK-Mel28), human early passage cultures (M010817 and M000921), and human B lymphoma cells (RL cells) were transfected with PBS or with mRNA encoding Fluc or human MLKL. Twenty four hours after transfection, cells were collected and analyzed by flow cytometry. The graph shows the percentages of sytox⁺ cells (left) and flow cytometric plots of transfected RL cells (right). The horizontal lines indicates the mean and the error bars depict the standard deviation. b Newborn NSG mice (2 days) were sublethally irradiated and subsequently received 1 × 10⁵ CD34⁺ human stem cells isolated from HLA-A2-positive cord blood by injection in the liver. Thirteen weeks after stem cell transfer, 2.5 × 10⁶ human RL follicular lymphoma cells were inoculated s.c. into the mice. On days 11 and 15 (treatments 1 and 2, respectively), the tumors were injected with saline (n = 6) or 10 µg mRNA encoding Fluc (n = 6) or human MLKL (n = 9) followed by electroporation. Starting 8 days after tumor inoculation and during the treatments, 30 µg Flt3 ligand was given daily. Tumor growth was measured over time. The animals were culled when the tumor had reached a size of 100 mm². ****p < 0.001 (log-rank test of Kaplan–Meier curves)